LivaNova (NASDAQ:LIVN)‘s stock had its “hold” rating reaffirmed by stock analysts at BTIG Research in a research report issued to clients and investors on Thursday.
Several other equities research analysts have also issued reports on the stock. Jefferies Financial Group boosted their price target on shares of LivaNova to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd. Zacks Investment Research lowered shares of LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Stifel Nicolaus boosted their target price on shares of LivaNova from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, September 17th. BidaskClub downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $135.00 target price (up previously from $128.00) on shares of LivaNova in a research note on Wednesday, August 1st. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $113.33.
Shares of LivaNova stock opened at $111.99 on Thursday. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of 33.83, a price-to-earnings-growth ratio of 3.17 and a beta of 0.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.08 and a current ratio of 1.51. LivaNova has a 52-week low of $72.30 and a 52-week high of $131.54.
In other news, insider Douglas John Manko sold 2,058 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $121.61, for a total value of $250,273.38. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $121.58, for a total transaction of $121,580.00. The disclosure for this sale can be found here. Insiders sold a total of 8,058 shares of company stock worth $963,033 in the last 90 days. 0.41% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. lifted its position in LivaNova by 4.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 286,372 shares of the company’s stock worth $28,586,000 after buying an additional 12,517 shares in the last quarter. BlackRock Inc. lifted its position in LivaNova by 6.1% during the 2nd quarter. BlackRock Inc. now owns 5,393,015 shares of the company’s stock worth $538,332,000 after buying an additional 309,138 shares in the last quarter. Cibc Bank USA acquired a new position in LivaNova during the 3rd quarter worth about $227,000. Point72 Europe London LLP lifted its position in LivaNova by 103.2% during the 2nd quarter. Point72 Europe London LLP now owns 71,872 shares of the company’s stock worth $7,174,000 after buying an additional 36,500 shares in the last quarter. Finally, Twin Tree Management LP acquired a new position in LivaNova during the 2nd quarter worth about $963,000. Institutional investors own 87.18% of the company’s stock.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Read More: What are the Benefits of Index Funds?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.